Combined changes in albuminuria and kidney function and subsequent risk for kidney failure in type 2 diabetes.
albuminuria
diabetes mellitus
function
kidney function tests
type 2
Journal
BMJ open diabetes research & care
ISSN: 2052-4897
Titre abrégé: BMJ Open Diabetes Res Care
Pays: England
ID NLM: 101641391
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
07
04
2021
accepted:
29
05
2021
entrez:
1
7
2021
pubmed:
2
7
2021
medline:
12
8
2021
Statut:
ppublish
Résumé
Changes in albuminuria or estimated glomerular filtration rate (eGFR) can be used as a surrogate endpoint of end-stage kidney disease (ESKD) in people with type 2 diabetes. We investigated whether the combined changes in albuminuria and eGFR are more strongly associated with future risk of ESKD. Using data from a multicenter observational cohort study of people with type 2 diabetes, we evaluated the association of percentage change in urine albumin to creatinine ratio (UACR) and/or annual change in eGFR over 2 years with subsequent ESKD risk. Among 1417 patients with repeated albuminuria and eGFR over 2 years, 129 (9.1%) developed ESKD. Patients with >30% UACR decline had lower ESKD risk (HR 0.47; 95% CI 0.29 to 0.77), whereas those with >30% UACR increase had higher ESKD risk (HR 2.31; 95% CI 1.52 to 3.51), compared with those with minor UACR change. Patients with greater eGFR decline had an increased ESKD risk than those with minor eGFR change (a decline of <2.5 mL/min/1.73 m Combined changes in albuminuria and eGFR over 2 years were strongly associated with future risk of kidney failure in patients with type 2 diabetes.
Identifiants
pubmed: 34193460
pii: 9/1/e002311
doi: 10.1136/bmjdrc-2021-002311
pmc: PMC8246293
pii:
doi:
Types de publication
Journal Article
Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
J Am Soc Nephrol. 2019 Sep;30(9):1735-1745
pubmed: 31292197
Diabetes Technol Ther. 2020 Nov;22(11):828-834
pubmed: 32348695
J Am Heart Assoc. 2020 Sep 15;9(18):e016976
pubmed: 32893717
Diabetes Care. 2019 May;42(5):891-902
pubmed: 30833372
Diabetes Care. 2018 Aug;41(8):1646-1653
pubmed: 29858211
J Am Soc Nephrol. 2019 Sep;30(9):1756-1769
pubmed: 31292198
J Am Soc Nephrol. 2015 Aug;26(8):2055-64
pubmed: 25421558
J Am Soc Nephrol. 2020 Dec;31(12):2925-2936
pubmed: 32998938
Clin Exp Nephrol. 2014 Aug;18(4):613-20
pubmed: 24132561
J Am Soc Nephrol. 2016 Aug;27(8):2447-55
pubmed: 26657867
Nephrol Dial Transplant. 2011 Sep;26(9):2924-30
pubmed: 21303964
Kidney Int. 2014 Jan;85(1):49-61
pubmed: 24284513
N Engl J Med. 2020 Oct 8;383(15):1436-1446
pubmed: 32970396
Diabetologia. 2019 Nov;62(11):1988-1997
pubmed: 31302707
N Engl J Med. 2019 Jun 13;380(24):2295-2306
pubmed: 30990260
Am J Kidney Dis. 2020 Jan;75(1):84-104
pubmed: 31473020
J Diabetes Investig. 2010 Oct 19;1(5):212-28
pubmed: 24843435
JAMA. 2016 Aug 9;316(6):602-10
pubmed: 27532915
Lancet Diabetes Endocrinol. 2019 Feb;7(2):115-127
pubmed: 30635225
BMJ Open Diabetes Res Care. 2020 Mar;8(1):
pubmed: 32205326
Clin J Am Soc Nephrol. 2019 Jun 7;14(6):862-872
pubmed: 31160317
Am J Kidney Dis. 2014 Dec;64(6):821-35
pubmed: 25441437
Am J Kidney Dis. 2009 Jun;53(6):982-92
pubmed: 19339088